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BACKGROUND: Core Outcome Sets (COSs) are necessary to standardize reporting in
research studies. This is urgently required in the field of chronic subdural hematoma
(CSDH), one of themost common disease entities managed in neurosurgery and the topic
of several recent trials. To complement thedevelopmentof aCOS, a standardizeddefinition
and baseline Data Elements (DEs) to be collected in CSDH patients, would further improve
study quality and comparability in this heterogeneous population.
OBJECTIVE: To, first, define a standardized COS for reporting in all future CSDH studies;
and, second, to identify a unified CSDH Definition and set of DEs for reporting in future
CSDH studies.
METHODS: The overall study design includes a Delphi survey process among 150 respon-
dents from2main stakeholder groups: healthcare professionals or researchers (HCPRs) and
Patients or carers. HCPR, patients and carers will all be invited to complete the survey on
the COS, only the HCPR survey will include questions on definition and DE.
EXPECTED OUTCOMES: It is expected that the COS, definition, and DE will be developed
through this Delphi survey and that these can be applied in future CSDH studies. This is
necessary to help align future research studies on CSDH and to understand the effects of
different treatments on patient function and recovery.
DISCUSSION: This Delphi survey should result in consensus on a COS and a standardized
CSDH Definition and DEs to be used in future CSDH studies.
KEYWORDS: Chronic subdural hematoma, Core Outcomes and Data Elements, Delphi
Neurosurgery 89:720–725, 2021 https://doi.org/10.1093/neuros/nyab268 www.neurosurgery-online.com
GENERAL INFORMATION
Protocol title: Defining Core Outcomes and
Data Elements (CODEs) in chronic subdural
hematoma (CSDH), CODE-CSDH, 2021.
This protocol was approved by the University
Hospitals Plymouth NHS Trust, Derriford
Hospital, Plymouth, PL6 8DH, UK (Reference
CA_2020-21-303) and registered at clinical-
trials.gov on April 14, 2021 with Identifier
NCT04850612. This study is supported by The
Netherlands Organisation for Health Research
and Development (ZonMw project number
843002824, 2017), Postbus 93 245, 2509 AE
The Hague, The Netherlands.
ABBREVIATIONS: CODEs, Core Outcomes and Data
Elements; COS, Core Outcome Set; COS-STAD, Core
Outcome Set-Standards for Development; CSDH,
chronic subdural hematoma; DEs, Data Elements;
HCPRs, healthcare professionals or researchers
RATIONALE AND BACAKGROUND
INFORMATION
CSDH is a collection of blood and fluid
surrounded by membranes that accumulates
on the brain surface over weeks to months
(Figure 1A). It predominately affects older
people and often has a delayed association with
a preceding head trauma. Patients commonly
present with symptoms such as confusion, unbal-
anced walking, limb weakness, and headaches.
This might differentially lead to suspicion of
stroke, although the onset is more gradual, and
computed tomography (CT) imaging of the head
is diagnostic (Figure 1B).
The incidence of CSDH has been increasing
rapidly from 1.7 to 31 per 100 000 persons
per year up to 2000, to around 20 to 80 per
100 000 persons per year from 2000 to 2019.1-4
The projected increase in incidence implies
that CSDH may become the most common
neurosurgical condition treated in adults.5 The
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FIGURE 1. A, Anatomic location of CSDH: graphic highlighting layers overlying the brain involved in CSDH. B, Anatomic
location of CSDH: corresponding CT image of CSDH showing area of low density (dark gray) on the right side of the image.
mainstay of treatment is surgical drainage of the collection and
patients spend an average of 7 d in the neurosurgery unit.6
There has been significant growth in the number of CSDH
publications in recent years mirroring progress in potential
management options and outcomes.7 Interest in alternatives to
surgery including drug therapies and radiological occlusion of
blood vessels is growing, but the efficacy of these alternatives is
yet to be established.8-11 Currently, there is wide variation in
how and when patient outcome is measured among studies,12
making it difficult to conclusively compare between studies or
generalize the data to a wider population. Much could be gained
by agreeing a minimum set of standardized outcomes that should
be measured and reported in all CSDH studies, known as a Core
Outcome Set (COS).13,14 A COS will help align future research
studies and is necessary to understand the effect of different
treatments on patient function and recovery. To ensure study
results are relevant, the COS needs to be informed by what is
important to patients as well as to clinicians and researchers. In
addition to outcomes, the type of patient included in CSDH
studies and baseline data reported on them varies greatly.15
A standardized definition of CSDH and set of baseline Data
Elements (DEs) would help clarify the populations being studied.
This is important as outcomes in CSDH patients can be influ-
enced by different patterns on imaging,16 operative techniques
employed,17 and patient baseline characteristics.18
An established process for development of a COS and how this
should be reported is already defined by the COS-STAP (Core
Outcome Set-Standardized Protocol items) group and is adhered
to in the design of this protocol.19 We have followed a design
already reported by the CORMAC (Core Outcome Research
Measures in Anal Cancer) and OMERACT (Outcome MEasures
in Rheumatoid Arthritis Clinical Trials) groups, whereby aDelphi
survey is used to gain agreement among healthcare professionals
and patients on what is important when measuring outcome.20,21
This is described in further detail in the methodology section. To
help overcome potential barriers of implementing a COS, we will
seek to include international perspectives from healthcare profes-
sionals and researchers already involved in the field of CSDH such
that the COS will be endorsed by those conducting the research.
STUDY GOALS ANDOBJECTIVES
The scope of this study is determined as per the COS-Standards
for Development (COS-STAD) recommendations.22 The COS
is to be applied to any research studies or trials that include
adult patients diagnosed with CSDH. The COS will cover all
interventions including surgical, radiological, medical, and obser-
vation. The primary objective is to define a standardized COS
for reporting in all future CSDH studies through a Delphi
survey process including all relevant stakeholders. The secondary
objective is to identify a unified CSDH definition and set of DEs
for reporting in future CSDH studies, through a Delphi survey
process including healthcare professional or researcher (HCPR)
stakeholders.
STUDY DESIGN
The overall study design includes a Delphi survey process.23
This is a process whereby all outcomes and DEs from the CSDH
literature and expert opinion are presented to a large group of
patients, carers, and HCPR via a survey. Each survey participant
has the opportunity to rank the elements and outcomes in levels
of importance to them, and the survey is then repeated including
presentation of the results from the first round, in order to attempt
to gain agreement between participants on what is important. All
elements are then reviewed at a final “consensus” meeting.
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FIGURE 2. Study flowchart.
METHODOLOGY
Participant Eligibility for Delphi Survey
In line with COS-STAD, 2 main stakeholder groups will be
included to complete the survey; HCPRs and Patients or carers.
See Figure 2 for the study flow chart.
HCPR will include those who conduct research in CSDH
and those with experience in managing different aspects of
patient care for CSDH, including but not limited to neurosur-
geons, neurologists, anesthetists, neuroradiologists, elderly care
physicians, neurorehabilitation specialists, general practitioners,
CSDH researchers, and clinical nurse specialists.
Patients will be eligible for participation if they are adults
(≥18 yr of age) and if they were admitted to a neurosurgical unit
with a diagnosis of CSDHwithin the last 5 yr. In the cases where a
patient lacks capacity to give consent, a carer will be invited to take
part on their behalf. It is critical to include the carers, as a consid-
erable number of patients with CSDH have cognitive deficits
prior to surgery, which will preclude them from having capacity to
take part. These patients have different outcomes and care needs,
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which are important to consider in COSs and, therefore, we are
grateful to carers who can advocate for them.
Number of Participants
Previous COS development studies have reported 140 to 150
respondents.20,21 To reach a similar number of stakeholders,
it is estimated that 50 to 60 neurosurgeons will participate,
as this is the primary group involved in CSDH management.
The remaining HCPR stakeholder groups should contribute a
further 50 to 60 responses combined and patient/carer stake-
holders approximately 20 to 30 responses. No new participants
will be invited after completion of round 1 and it will be stressed
that participation includes taking part in2 rounds with the aim to
minimize attrition.
Participant Recruitment
To incorporate all the appropriate HCPRs, the main sources
of invitation will include colleagues and research collaborators of
the study investigators, Society of British Neurological Surgeons
(SBNS), Dutch Subdural Hematoma Research (DSHR) group,
Nederlandse Vereniging voor Neurochirurgie (NVvN), Canadian
Neurosurgical Society—iCORIC (international COllaborative
Research Initiative in CSDH), and a group of international
clinical researchers with specific experience specific to CSDH.
The survey will also be advertised on social media platforms
accessed by relevant HCPR with contact details available to
receive full information and access to the survey. Those who agree
to take part will be asked to invite other relevant colleagues or
societies thus increasing the uptake through the “snowball” effect.
Patients (or their carer), who were admitted with a diagnosis
of CSDH in the participating neurosurgical unit (University
Hospitals Plymouth NHS Trust) will be sent information by post
to either decline or accept an interest in taking part. A follow-up
phone call will take place from a trained clinical member of the
study team if no response is received. Patients who indicate an
interest in participation will receive further information via email,
phone, or post depending on their preference.
Survey Development
This is a process of iterative surveys, with completion
by all stakeholders over2 rounds. The online survey will be
delivered using a datamanagement open-source software program
(LimeSurvey, version 2.06LTS) in both rounds.
For the development of this study, the investigators will review
the data collected from three sources: (1) systematic reviews on
CODEs,12,15 (2) data reported in recent systematic review of on-
going CSDH trials,7 which enables inclusion of any more recent
data that may not have been captured in the earlier published
CODE reviews, and (3) expert opinion from the study investi-
gators regarding any additional elements not already included.
For HCPR, these data will be amalgamated into 2 Delphi
surveys: a COS survey and a definition and DEs survey. The
COS-survey summarizes all potential outcomes in CSDH, which
will be categorized into the following key domains: mortality,
recurrence, complications, functional outcome, and radiological
outcome. In addition to ranking the importance of each domain
we will aim to identify key components of each domain (eg,
measure of functional outcome) and the time points at which
they should be reported. The definition and DE survey summa-
rizes key elements relating to the definition of CSDH and baseline
data on patients diagnosed with CSDH.
The patient/carer survey will be adapted to contain simplified
language appropriate to a non-HCPR audience and will be
reviewed by the patient representative. It will contain the same
core outcomes as the HCPR survey, but may be worded differ-
ently and each term will be explained in full. The definition and
DE survey will not be included for patients as this refers to the
diagnosis and assessment of CSDH, which is only relevant to
clinicians.
The surveys will only be available in the English language.
Survey Process
The target is for all participants to partake in both rounds
of the survey. Each survey will be circulated with an email (or
phone consultation) explaining its purpose and a reminder email
will be sent to encourage a high response rate. At the start of
each survey, HCPR participants will be asked to identify their
specialty, their level of training, and the country they practice in.
The latter to ensure we have good geographical spread of repre-
sentation. Patients/carer will be asked to identify whether they
are a patient or carer and their age. These basic demographics will
maintain anonymity but enable us to understand the spread of
people taking part.
In round 1, HCPR participants will be asked to rank all options
in the survey on a 9-point Likert scale, from very unimportant
(1) to very important (9). A score of 7 to 9 will be evaluated
as being critically important and 1 to 3 as limited importance.
Patients/carer participants will be asked to rank all options in the
survey on a 5-point Likert scale, from very unimportant (1) to
very important (5). A score of 4 to 5 will be evaluated as being
critically important and 1 to 2 as limited importance.
In round 2, the anonymized summary results from round
1 will be presented, categorized by stakeholders (HCPR or
patients/carers). Participants will be asked to rank the outcomes
again with this knowledge in mind. All outcomes from round 1
will be included in round 2 and with any suggested new additions
made in round 1.
The aim is to formulate a list of outcomes that the majority
of all stakeholders agree are “critically important” for inclusion in
the final COS. Agreement on a CSDH definition and DE will
also be sought. If consensus cannot be reached in the majority of
outcomes, then a third round may be conducted, repeating the
process from round 2, before a final consensus meeting is held.
Consensus Meeting
After survey completion the study, investigators will review the
results for inclusion in the final proposed COS, definition, and
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DE and assign each outcome to one of three categories:
(1) An element will be included if 70% or more of respondents
rate the element as critically important (7-9) AND 15% or
fewer rate it as limited importance (1-3).
(2) The element will be excluded if 70% or more respondents
rate the element as limited important (1-3) AND 15% or
fewer rate it as critically important (7-9).
(3) When neither of the above criteria is met, this requires a more
elaborate discussion at the consensus meeting.
These 3 categories will be discussed during the final (virtual)
consensus meeting. In addition to the study investigators, a
selection of iCORIC members from different international sites
who have specialized experience in CSDH trials will be invited.
The elements in category 1 and 2 will be presented first. If
participants have a fundamental reason to include or exclude a
certain element, this will be discussed. The attendees will take
an electronic poll to confirm that >70% of those in atten-
dance agree on inclusion or exclusion of the selected elements
in the COS, definition, and DE. The elements from category 3
will be discussed and voted on, using the 9-point Likert scale.
If consensus cannot be met by >70% of participants, these
items will be reviewed together. Individual contrasting views
will be evaluated and all participants will have an equal oppor-
tunity to explain their point of view before reiteration of the
voting. Outcomes meeting the criteria for category 1 will then
be included in the COS; all other items will be disregarded.
DISCUSSION
CSDH is increasing in incidence and a growing research focus.
There is no international consensus on a standardized COS in
CSDH, which is necessary to help align future research studies
and understand the effect of new treatment strategies on patient
function and recovery. This will be complemented by devel-
oping a clear definition of CSDH and a set of baseline DEs
reportable in studies. It is expected that consensus on a CSDH
COS, definition, and baseline data element set will be reached
through this Delphi survey involving relevant patient, carer, and
healthcare professional and researcher stakeholders.
TRIAL STATUS
This study commenced onMay 3 2021. The first round of this
Delphi process was completed on July 12 2021.
SAFETY CONSIDERATIONS
Due to the voluntary nature of the survey and ability to
withdraw participation at any time point there are no perceived
risks to participants.
FOLLOW-UP




Descriptive statistics showing the distribution of responses
from each round of the survey will be displayed in the subsequent
round. Highlighting the dropout rate between rounds, with an
aim to have a minimum of 70% of participants from round 1
taking part in round 2.
QUALITY ASSURANCE
All data will be stored securely and all individuals accessing
any of the data will comply with the requirements of the Data
Protection Act 2018 and the General Data Protection Regulation
(GDPR) and its statements regarding the collection, storage,
processing, and disclosure of any personal information.
EXPECTED OUTCOMES OF THE STUDY
It is expected that a COS, definition, and DE will be developed
through this Delphi and that these will be used in future CSDH
studies. This is necessary to help align future research studies on
CSDH and to understand the effects of different treatments on
patient function and recovery.
DURATIONOF THE PROJECT
Rounds 1 and 2 are expected both to be completed within
6 wk. Evaluation of results after both rounds will demand 4 wk.
The estimated total duration is a maximum of 6 mo.
PROJECTMANAGEMENT
The survey will be distributed amongHCPR by authors DCH,
CI-M, and EE. Patients/carers will be contacted by EE at the
University Hospitals Plymouth NHS Trust.
ETHICS
Informed consent shall be requested through the first page of
the online survey and for patients/carers a verbal or email consent
will be recorded. The study protocol, consent forms, and survey
were approved by University Hospitals Plymouth NHS trust and
there were no ethical concerns.
Funding
This study did not receive any funding or financial support.
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